All News
ACTEMRA Gets "Breakthrough" Status from the FDA for Scleroderma
The FASSCINATE study presented at EULAR 2015 was instrumental in tocilizumab (TCZ) getting a nod from the FDA to develop TCZ for scleroderma.
Read Article
Vitamin D Fails in Postmenopausal Osteoporosis Prevention
JAMA reports that investigators from the University of Wisconsin in Madison studied the impact of vitamin D supplements on 230 women who were at least five years past menopause but no older than 75, and without osteoporo
Read ArticleLegionella Outbreak in NYC
An outbreak of Legionnaires' disease has killed four people and sickened 65 in the Bronx section of New York City since July 10, according to New York City health officials. This Legionnaires' outbreak is now more than five times the number of cases recorded in the last outbre
Read ArticleCDC Report: 22% of USA Population is Disabled
CDC has released the findings of its 2013 Behavioral Risk Factor Surveillance System (BRFSS), with 5 questions addressing different forms of disability - vision, cognition, mobility, self-care, and independent living. Overall, 22.2% of U.S. adults (53,316,677 persons) reported any disability.
Read Article
NSAIDs are Risky in Patients with Chronic Kidney Disease
Little is known about what happens when NSAIDs are used in patients with chronic kidned disease (CKD), especially those with hypertension.
Read Article
Lipid Levels and CV Events in RA
Rheumatoid arthritis not only affects the joints but can also increase risk for cardiovascular disease. The mechanism of the increased risk of cardiovascular disease in rheumatoid arthritis remains uncertain.
Read ArticleB cell Inhibition with Epratuzumab Fails in Two Phase III Lupus Trials
Targeting B cells in systemic lupus erythematosus, the prototypic autoimmune disorder, has long been an attractive target for researchers. Despite negative trials with rituximab and the limited success of belimumab, efforts to inhibit B cell activity have continued.
Read Article
Men and Blacks Undertreated for Osteoporosis
Using claims data from 36,965 patients in an Indiana database, researchers found women (OR 1.86) and non-black patients (OR 1.52) were more likely to be treated (p<0.001) for osteoporosis.
Read Article
Gut Dysbiosis in RA Reflects Activity, Serology and Response
Using a metagenome-wide association study (MGWAS) of fecal, dental and salivary samples from rheumatoid arthritis and healthy controls, Zhang et al showed that gut and oral microbiomes are highly concordant and that in RA there is a distinct dysbiosis with less Haemophilus spp.
Read Article
Is Morning Stiffness Important?
Morning stiffness? An oft-asked question, but does it have reliable discriminatory value?
Read Article
Not All Placebos are Equal: The Needle is Mightier than the Pill
Placebos are necessary to determine the “true effect” of any medical intervention. As such, they have become the cornerstone of evidence-based medicine, randomized controlled clinical trials and novel drug development.
Read Article
2015 Guidelines for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing form of interstitial pneumonia, with poor survival rates of nearly 50% at 3 years.
Read Article
Psoriasis and Psoriatic Arthritis Have an Increased Risk of Gout
The frequency of gout among patients with psoriatic disease was studied in two cohorts of 98,810 patients from the Health Professionals Follow-up Study (1986-2010) and the Nurses' Health Study (1998-2010).
Read ArticleWhat's Your Diagnosis? Truncal Rash, Arthritis and +ANA
An 80 year old woman complains of 3 months of rash on her back. It is modestly pruritic. The lesions are both annular and papular appearing over her back, torso and upper arms. She also complains of pain and swelling in her fingers.
Read Article
Tacrolimus Tops Other DMARDs as Induction Therapy for Lupus Nephritis
Metanalysis of nine clinical trials and 972 lupus patients examined the comparative efficacy of tacrolimus, mycophenolate (MMF) and cyclophosphamide (CYC) as induction therapy for lupus nephritis.
Read Article
Outcry Over the Cost of Drugs
Several news articles have addressed the rising concern by patients and physicians over the cost of newer drugs. This issue comes to a head as more than 100 oncologists from top cancer hospitals around the U.S.
Read Article
Long term Denosumab Use Shows Favorable Outcomes: Results from the FREEDOM Extension Trial
Osteoporosis is a disease characterized by increased bone loss that outpaces the grown of new bone. As a result bones become less dense and more fragile and brittle; porous bones are more prone to fracture.
Read Article
DSB: Drug Shortages July 2015
Several drugs continue to be in short supply, posing significant problems for patients. Foremost on this list is leflunomide (Arava) which is backordered for both 10 mg and 20 mg tablets.
Leflunomide Shortage
Read Article
Allopurinol Risky in Asian Population
The go-to drug to treat hyperuricemia and gout, allopurinol, put patients at risk for developing hypersensitivity when American College of Rheumatology guidelines weren't followed, a large database study found.
Read ArticleRituximab Induced Serum Sickness
Karmacharya and colleages have reviewed 33 cases of rituximab-induced serum sickness. Half of these patients had the classic triad of SS fever, rash, and arthralgia and a self-limiting course. The time to onset after infusion was greater with the first dose of rituximab c
Read Article